Skip to main navigation

Careers

About Us
Scientific Focus

Our Focus

Our Platform Technologies:
Turbo-ZM™ RMAs / ERSGs
Class 1 CF
Pipeline

Pipeline

Class 1 CF

RDEB/JEB

FAP & CRC
Scientific Documents
Investors

Overview

Press Releases

Events & Presentations

Corporate Governance

Financials and Filings

Stock Information

Analyst Coverage

Investment Inquiries

Press Releases

Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investment Inquiries

Year

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

November 13, 2023

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

October 9, 2023

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

September 19, 2023

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

September 18, 2023

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

September 7, 2023

Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update

August 14, 2023

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

August 14, 2023

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

August 3, 2023

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

July 10, 2023

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

June 28, 2023

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

TURBO-ZM is a trademark of Eloxx Pharmaceuticals, Inc..
©2023 Eloxx Pharmaceuticals, Inc.
Produced in the USA.
November 2023

Privacy Policy | Contact Us